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Prostate cancer is the most common cancer in men in the 
UK, with over 42,000 men being diagnosed with the con-
dition every year.1 According to Prostate Cancer UK, there 
are more than 330,000 men currently living with prostate 
cancer in the UK. The use of prostate-specific antigen 
(PSA) testing has led to an overall increase in the inci-
dence of prostate cancer rates.2 With early detection and 
more effective treatment, survival of patients with the dis-
ease has improved. However, despite improvements in 
care, there are significant variations in prostate cancer out-
comes across the UK.3 We therefore need to make sure that 
those men receive the best possible care and support they 
need to live with prostate cancer regardless of where they 
live. In June 2015, the National Institute for Health and 
Care Excellence (NICE) published its quality standards for 
prostate cancer to reduce inconsistencies in the care of 
patients diagnosed with prostate cancer.4
National Institute for Health and Care 
Excellence
NICE is an independent organization, which was origi-
nally set up by the government in 1999 as the National 
Institute for Clinical Excellence. Its aim was to end the 
‘postcode lottery’ of care in the NHS and to ensure equal 
access to treatment irrespective of where someone lived. 
In 2005, NICE merged with the Health Development 
Agency and started developing public health guidelines. It 
changed its name to the National Institute for Health and 
Care Excellence. The Health and Social Care Bill 2012 re-
established NICE as a non-departmental public body with 
an emphasis on the development of outcomes at a local 
and national level by creating clinical and public health 
guidelines as well as quality standards. NICE currently 
only provides guidance for the NHS in England and Wales.
NICE quality standards
The NICE quality standards programme was established in 
2009. Quality standards are ‘a comprehensive set of recom-
mendations for a particular disease or condition, particular 
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need or service’.5 They are a set of concise, specific state-
ments that ‘act as markers of high-quality and cost-effec-
tive patient care’5 and are derived from evidence-based 
guidance. They are developed to drive measurable quality 
improvements in areas where care is variable. Quality 
standards can be used both at a local level as audit crite-
ria and at a national level as part of the Care Quality 
Commission inspection activities or national audits to 
achieve the best outcomes for patients.
Prostate cancer quality standards
The concept of prostate cancer standards was first devel-
oped in Europe in 2011 by the European School of 
Oncology (ESO) through its prostate cancer programme. 
In its collaborative article ‘The requirements of a specialist 
prostate cancer unit: a discussion paper from the European 
School of Oncology’, the ESO highlighted the importance 
of adopting a multidisciplinary approach to manage pros-
tate cancer patients.6 The paper introduced the idea of 
prostate cancer units (PCUs) and suggested reorganising 
prostate cancer care in Europe around a network of PCUs 
to improve standards of care and management. In 2012, 
the PCU initiative was therefore launched in Europe.7 A 
multidisciplinary task force was created and after a two-
year-long process, it came up with 40 standards deemed 
mandatory for quality prostate cancer care in PCUs.
In 2014, the European Association of Urology (EAU) 
noted the absence of standardised outcomes for men with 
localised prostate cancer. A working group was therefore 
put together to develop a ‘standard set’ of 10 to 15 outcomes 
that should be tracked for all patients with localised disease 
to compare differences in outcomes in different centres.8
Prostate Cancer UK published a report in 2013 on pros-
tate cancer services in the UK, highlighting the so-called 
‘postcode lottery’ of cancer care and the significant varia-
tions in the treatment that prostate cancer survivors receive. 
Differences were noted in prostate cancer incidence, 
patient experience, mortality and survival across the UK.9 
To address those issues, Prostate Cancer UK developed a 
quality checklist made up of 15 standards, which outlines 
the quality of care men with prostate cancer should expect 
to receive across the UK, regardless of where they live.10
In 2014, Tackle Prostate Cancer, a charity organisation 
in the UK, formed a working group consisting of prostate 
cancer patients and healthcare professionals, and identified 
nine quality standards to ensure that men with prostate can-
cer receive the best possible care and support.11 The quality 
statements were also submitted to NICE to help with the 
development of its quality standards for prostate cancer.
In June 2015, NICE finally published five key state-
ments regarding prostate cancer care to drive quality 
improvements in patient safety, patient experience and clin-
ical effectiveness.4 The quality standards, which are mostly 
derived from the NICE prostate cancer guidelines,12 cover 
the care of men in secondary care who have been diagnosed 
with prostate cancer. They also cater for patients with pros-
tate cancer who are being followed up in primary care. 
Unlike the Tackle Prostate Cancer statements, the NICE 
quality standards do not cover the recognition and referral 
of men with suspected prostate cancer in primary care. This 
will instead be covered in a separate quality standard docu-
ment on referral for suspected cancer. The five NICE qual-
ity statements are listed in Table 1.
Quality statement 1: discussion with a 
named clinical nurse specialist
The 2014 National Cancer Patient Experience Survey 
(NCPES) highlighted that 88% of men diagnosed with 
prostate cancer were given the name of a clinical nurse spe-
cialist (CNS) compared to 93% of patients diagnosed with 
Figure 1. Flowchart showing the quality standards 
development process.
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breast cancer.13 CNSs are key clinical contacts with whom 
patients can have a discussion about their treatment options 
immediately after diagnosis. They are there to answer any 
questions or concerns the patients might have during the 
course of their care. The NCPES showed that patients with 
a CNS are more likely to report a positive experience of 
their care. It is therefore vital that commissioners and pros-
tate cancer services ensure that they have sufficient nurse 
specialists to support men with prostate cancer.
Quality statement 2: treatment 
options
Patients who have been diagnosed with low-risk prostate 
cancer should be offered the choice between radical treat-
ment and active surveillance (AS). They should be offered 
the most up-to-date information and be given the opportu-
nity to discuss the pros and cons of the various treatment 
options. AS can potentially reduce overtreatment and 
avoid treatment-related side-effects, thereby reducing 
costs.14 Members of the urology multidisciplinary team 
(MDT) should therefore be trained in counselling patients 
to help them make an informed decision about their treat-
ment, including AS.
Quality statement 3: combination 
therapy
Men with intermediate or high-risk localised prostate can-
cer, who are offered non-surgical treatment, should be 
offered radical radiotherapy in combination with androgen 
deprivation therapy (ADT). The combination has shown 
better outcomes compared to radical radiotherapy alone. A 
European randomised study demonstrated that a group 
who received combined luteinising hormone-releasing 
hormone analogue and radical radiotherapy had a 79% 
five-year overall survival compared with a group treated 
with radical radiotherapy alone.15 This is now recom-
mended in both NICE and EAU guidelines. In contrast, 
several studies have also shown that in locally advanced 
disease, combined radiotherapy and ADT is superior to 
ADT alone.16–19 Healthcare professionals should familiar-
ise themselves with the guidance to offer the best possible 
care to those patients.
Quality statement 4: managing 
adverse effects of treatment
Lower urinary tract symptoms and erectile dysfunction 
(ED) are common side-effects associated with prostate 
cancer treatment. Research into wellbeing services for 
men with prostate cancer has shown that 63% of men with 
prostate cancer suffer from ED and 38% complain of uri-
nary incontinence.20 Gastrointestinal symptoms after radi-
cal radiotherapy can also have an impact on quality of life, 
resulting in psychological distress and depression. 
According to the NCPES in 2014, 44% of patients were 
not fully counselled about the potential side-effects before 
they started treatment for prostate cancer. Local arrange-
ments and pathways should therefore be put in place to 
allow patients to have access to specialist services to man-
age the adverse effects of treatment with on-going support 
from the urology MDT.
Quality statement 5: hormone-
relapsed metastatic prostate cancer
Men with hormone-relapsed metastatic prostate cancer 
should have their treatment options discussed by the urol-
ogy cancer MDT. Those patients often require the multi-
disciplinary involvement of the oncologist, urologist, 
cancer nurse specialist, palliative care and acute pain 
teams to optimise their comfort and quality of life. By 
discussing their cases in the MDT, we can involve the 
oncology team in their care from the start and we can 
discuss suitable treatment options for them, with pallia-
tive care made available if and when needed.
Discussion
To reduce the variation in treatment, NICE developed five 
quality standards to outline the care men with prostate 
Table 1. NICE quality standards for prostate cancer.
Quality standard 1 Men with prostate cancer have a discussion about treatment options and adverse effects with a 
named nurse specialist.
Quality standard 2 Men with low-risk localised prostate cancer for whom radical prostatectomy or radical 
radiotherapy is suitable are also offered the option of active surveillance.
Quality standard 3 Men with intermediate or high-risk localised prostate cancer who are offered non-surgical radical 
treatment are offered radical radiotherapy and androgen deprivation therapy in combination.
Quality standard 4 Men with adverse effects of prostate cancer treatment are referred to specialist services.
Quality standard 5 Men with hormone-relapsed metastatic prostate cancer have their treatment options discussed 
by the urology cancer multidisciplinary team.
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cancer are expected to receive, regardless of where they 
live. Among the key themes expressed in the NICE state-
ments is the fact that patients need the appropriate support 
from a CNS to discuss their treatment options as well as 
support from specialist services to manage the adverse 
effects of prostate cancer treatment. Also, men should 
receive the best possible treatment based on current evi-
dence and guidelines. AS should be offered as an option to 
patients with low-risk disease and radical radiotherapy 
should be offered in combination with ADT to patients 
with localised intermediate to high-risk disease being con-
sidered for non-surgical treatment. Those with hormone-
relapsed metastatic disease should have their treatment 
options discussed in the urology cancer MDT. Finally, the 
quality statements highlight the role of the different mem-
bers of the MDT to ensure that patients are fully supported 
at each stage of their cancer journey.
As mentioned previously, the quality standard does not 
cover the referral of men with suspected prostate cancer 
and PSA testing. This will be covered in a separate quality 
standard document. Although discussed by the advisory 
committee, the use of robotics was not an area for quality 
improvement and therefore was not included in the draft 
document. The committee felt that this area was already 
being addressed by NHS England as part of specialised 
commissioning.
Conclusions
Prostate cancer is expected to be the most common cancer 
in the UK by 2030.9 With the increase in the number of new 
cases and the number of survivors, there is a need to 
improve the quality of care experienced across the UK. The 
development of the NICE prostate cancer quality standards 
is definitely a step in the right direction. However, there is 
still a long way to go when it comes to survivorship care 
and supported self-management of prostate cancer patients. 
Compliance with the NICE standards should nonetheless 
be audited in all prostate cancer units across the UK to 
achieve a gold standard of care.
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